







# Histopathology Assessment, Specimen Requirement and Histology Grading for Breast Cancers


**Dr Ahmed Nasir Hanifi** 

MBBS, FCPS (Histopathology).

ncc

Consultant Histopathologist and Cytopathologist.

Head of Department of Pathology, FMIC and CPHL, Kabul, Afghanistan.




### **OUTLINE OF PRESENTATION**

- 1. Importance of Histopathology in Breast Cancers
- 2. Difference between Histology and Cytology
- 3. Latest WHO classification of Breast Tumors
- 4. Specimen Requirement/Protocols for Histopathology Specimen.
- 5. How Grading of the breast cancer is done?
- 6. Most common Breast Cancer Types
- 7. Take Home Message




8. Brain-Storming Question-Answers

### 1. Importance Of Histopathology Breast Cancers






### 2. Difference between Histology and Cytology






- Study of tissues
- Complex



- Needs experienced Histopathologist
- Can be reported in 5-10 days



#### **CYTOLOGY**


- Study of cells
- Simple
- Cheaper
- High sensitivity
- Needs experienced cytopathologist
- Can be reported in 12-24 hours


### 3. Latest WHO classification of




#### **WHO Classification of Tumours of** the Breast


Edited by Sunil R. Lakhani, Ian O. Ellis, Stuart J. Schnitt, Puay Hoon Tan, Marc J. van de Vijver

























#### WHO classification of tumours of the breast

EPITHELIAL TUMOURS		Invasive papillary carcinoma	8503/3
Microinvasive carcinoma		Acinic cell carcinoma	8550/3
MINISTER SERVICE		Mucoepidermoid carcinoma	8430/3
Invasive breast carcinoma		Polymorphous carcinoma	8525/3
invasive carcinoma of no special type (NST)	8500/3	Oncocytic carcinoma	8290/3
Pleomorphic carcinoma	8022/3	Lipid-rich carcinoma	8314/3
Carcinoma with osteoclast-like stromal	- Comment	Glycogen-rich clear cell carcinoma	8315/3
glant cells	8035/3	Sebaceous carcinoma	8410/3
Carcinoma with choriocarcinomatous		Sallvary gland/skin adnexal type turnours	
features		Cylindroma	8200/0
Carcinoma with melanotic features		Clear cell hidradenoma	8402/0"
Invasive lobular carcinoma	8520/3	Eniths follows and the follows are	
Classic lobular carcinoma		Epithelial-myoepithelial tumours	
Solid lobular carcinoma		Pleomorphic adenoma	8940/0
Alveolar lobular carcinoma		Adenomyoepithelioma	8963/0
Pleomorphic lobular carcinoma		Adenomyoepithelioma with carcinoma	8983/3*
Tubulolobular carcinoma		Adenoid cystic carcinoma	8200/3
Mixed lobular carcinoma		Precursor lesions	
Tubular carcinoma	8211/3	Ductal carcinoma in situ	8500/2
Cribriform cardinoma	8201/3	Lobular neoplasia	GO-GOOJE.
Mucinous carcinoma	8480/3	Lobular carcinoma in situ	
Carcinoma with meduliary features		Classic lobular carcinoma in situ	8520/2
Meduliary carcinoma	8510/3	Pleomorphic lobular carcinoma in situ	
Atypical meduliary carcinoma	8513/3	Atypical lobular hyperplasia	
Invasive carcinoma NST with meduliary features	8500/3		
	obouya	Intraductal proliferative lesions	
Carcinoma with apocrine differentiation Carcinoma with signet-ring-cell differentiation		Usual ductal hyperplasia	
invasive micropapillary carcinoma	8507/3*	Columnar cell lesions including flat epithelial	
Metaplastic carcinoma of no special type	8575/3	atypia	
Low-grade adenosquamous carcinoma	8570/3	Atypical ductal hyperplasta	
Fibromatosis-like metapiastic carcinoma	8572/3	Papillary lesions	
Squamous cell carcinoma	8070/3		8503/0
Spindle cell carcinoma	8032/3	Intraductal papilloma	DOUGIU
Metaplastic carcinoma with		Intraductal papilloma with atypical	econo
meserichymal differentiation		hyperplasia	8503/0
mesenchymal differentiation Chondroid differentiation	8571/3	Intraductal papilloma with ductal	
	8571/3 8571/3	Intraductal papilloma with ductal carcinoma in situ	8503/2*
Chondroid differentiation		Intraductal papilioma with ductal carcinoma in situ Intraductal papilioma with lobular	8603/2*
Chondroid differentiation Osseous differentiation		Intraductal papilioma with ductal carcinoma in situ Intraductal papilioma with lobular carcinoma in situ	
Chondrold differentiation Osseous differentiation Other types of mesenchymal	8571/3	Intraductal papilioma with ductal carcinoma in situ Intraductal papilioma with lobular carcinoma in situ Intraductal papiliary carcinoma	8503/2* 8520/2
Chondrold differentiation Osseous differentiation Other types of mesenchymal differentiation	8571/3 8575/3	Intraductal papilioma with ductal carcinoma in situ Intraductal papilioma with lobular carcinoma in situ Intraductal papiliary carcinoma Encapsulated papiliary carcinoma	8620/2 8620/2 8603/2
Chondroid differentiation Osseous differentiation Other types of mesenchymal differentiation Mixed metaplastic carcinoma	8571/3 8575/3 8575/3	Intraductal papilioma with ductal carcinoma in situ Intraductal papilioma with lobular carcinoma in situ Intraductal papiliary carcinoma	8603/2* 8620/2 8603/2 8604/2
Chondroid differentiation Osseous differentiation Other types of mesenchymal differentiation Mixed metaplastic carcinoma Myoepithelial carcinoma Rare types	8571/3 8575/3 8575/3	Intraductal papilioma with ductal carcinoma in situ Intraductal papilioma with lobular carcinoma in situ Intraductal papiliary carcinoma Encapsulated papiliary carcinoma with	8620/2 8620/2 8603/2
Chondrold differentiation Osseous differentiation Other types of mesenchymal differentiation Mixed metaplastic carcinoma Myoepithelial carcinoma  Rare types Carcinoma with neuroendocrine features	8575/3 8575/3 8575/3 8962/3	Intraductal papilioma with ductal carcinoma in situ Intraductal papilioma with lobular carcinoma in situ Intraductal papiliary carcinoma Encapsulated papiliary carcinoma with invasion	8603/2* 8620/2 8603/2 8604/2
Chondrold differentiation Osseous differentiation Other types of mesenchymal differentiation Mixed metaplastic carcinoma Myoepithelial carcinoma  Rare types Carcinoma with neuroendocrine features Neuroendocrine turnour, well-differentiated	8575/3 8575/3 8575/3 8962/3	Intraductal papilioma with ductal carcinoma in situ Intraductal papilioma with lobular carcinoma in situ Intraductal papiliary carcinoma Encapsulated papiliary carcinoma Encapsulated papiliary carcinoma with invasion Solid papiliary carcinoma	8603/2* 8620/2 8603/2 8604/2 8604/3
Chondroid differentiation Osseous differentiation Other types of mesenchymal differentiation Mixed metaplastic carcinoma Myoepitheital carcinoma  Rare types Carcinoma with neuroendocrine features Neuroendocrine turnour, well-differentiated Neuroendocrine carcinoma, poorly	8571/3 8575/3 8575/3 8962/3 8246/3	Intraductal papilioma with ductal carcinoma in situ Intraductal papilioma with lobular carcinoma in situ Intraductal papiliary carcinoma Encapsulated papiliary carcinoma Encapsulated papiliary carcinoma with Invasion Solid papiliary carcinoma In situ Invasive	8503/2* 8520/2 8503/2 8504/2 8504/3 8509/2
Chondroid differentiation Osseous differentiation Other types of mesenchymal differentiation Mixed metaplastic carcinoma Myoepitheital carcinoma  Rare types Carcinoma with neuroendocrine features Neuroendocrine turnour, well-differentiated Neuroendocrine carcinoma, poorly differentiated (small cell carcinoma)	8575/3 8575/3 8575/3 8962/3	Intraductal papilioma with ductal carcinoma in situ Intraductal papilioma with lobular carcinoma in situ Intraductal papiliary carcinoma Encapsulated papiliary carcinoma Encapsulated papiliary carcinoma with invasion Solid papiliary carcinoma in situ Invasive Benign epithelial proliferations	8503/2* 8520/2 8503/2 8504/2 8504/3 8509/2
Chondroid differentiation Osseous differentiation Other types of mesenchymal differentiation Mixed metaplastic carcinoma Myoepitheital carcinoma  Rare types Carcinoma with neuroendocrine features Neuroendocrine turnour, well-differentiated Neuroendocrine carcinoma, poorty differentiated (small cell carcinoma) Carcinoma with neuroendocrine	8571/3 8575/3 8575/3 8962/3 8246/3 8041/3	Intraductal papilioma with ductal carcinoma in situ Intraductal papilioma with lobular carcinoma in situ Intraductal papiliary carcinoma Encapsulated papiliary carcinoma Encapsulated papiliary carcinoma with invasion Solid papiliary carcinoma in situ Invasive  Benign epithelial proliferations Scierosing adenosis	8503/2* 8520/2 8503/2 8504/2 8504/3 8509/2
Chondroid differentiation Osseous differentiation Other types of mesenchymal differentiation Mixed metaplastic carcinoma Myoepitheital carcinoma  Rare types Carcinoma with neuroendocrine features Neuroendocrine turnour, well-differentiated Neuroendocrine carcinoma, poorty differentiated (small cell carcinoma) Carcinoma with neuroendocrine differentiation	8571/3 8575/3 8575/3 8962/3 8246/3 8041/3 8574/3	Intraductal papilioma with ductal carcinoma in situ Intraductal papilioma with lobular carcinoma in situ Intraductal papiliary carcinoma Encapsulated papiliary carcinoma Encapsulated papiliary carcinoma with Invasion Solid papiliary carcinoma in situ Invasive  Benign epithelial proliferations  Sclerosing adenosis Apocrine adenosis	8503/2* 8520/2 8503/2 8504/2 8504/3 8509/2
Chondroid differentiation Osseous differentiation Other types of mesenchymal differentiation Mixed metaplastic carcinoma Myoepitheital carcinoma  Rare types Carcinoma with neuroendocrine features Neuroendocrine turnour, well-differentiated Neuroendocrine carcinoma, poorty differentiated (small cell carcinoma) Carcinoma with neuroendocrine	8571/3 8575/3 8575/3 8962/3 8246/3 8041/3	Intraductal papilioma with ductal carcinoma in situ Intraductal papilioma with lobular carcinoma in situ Intraductal papiliary carcinoma Encapsulated papiliary carcinoma Encapsulated papiliary carcinoma with invasion Solid papiliary carcinoma in situ Invasive  Benign epithelial proliferations Scierosing adenosis	8503/2* 8520/2 8503/2 8504/2 8504/3 8509/2

Dadiol acarinomalov aciomalos lacion		MALIGNANT LYMPHOMA	
Radial scar/complex scierosing lesion Adenomas			00000
Tubular adenoma	8211/0	Diffuse large B-cell lymphoma	9680/3
Lactaling adenoma	8204/0	Burkitt lymphoma	9687/3
Apocrine adenoma	8401/0	T-cell lymphoma	
Ductal adenoma	8503/0	Anapiastic large cell lymphoma, ALK-negative	9702/3
		Extranodal marginal-zone B-cell lymphoma	Bruzja
MERCHANIAN TIMOURO		of MALT type	9699/3
MESENCHYMAL TUMOURS		Folicular lymphoma	9690/3
Nodular fasciltis	8828/0*	r dirediai lymphonia	9090)3
Myofibroblastoma	8825/0		
Desmoid-type fibromatosis	8821/1	METASTATIC TUMOURS	
Inflammatory myofibroblastic turnour	8825/1		
Benign vascular lesions	9120/0	TUMOURS OF THE MALE BREAST	
Haemangioma Angiomatosis	A ISON	Gynaecomastia	
		Carcinoma	
Atypical vascular lesions Pseudoangiomatous stromal hyperplasia		Invasive carcinoma	8500/3
Granular cell turnour	9580/0	In situ carcinoma	8500/2
Benign peripheral nerve-sheath turnours	phonen		
Neurofibroma	9540/0	CLINICAL PATTERNS	
Schwannoma	9560/0		
Lipoma	8860/0	Inflammatory carcinoma	8530/3
Angiolipoma	8861/0	Bilateral breast carcinoma	
Liposarcoma	8860/3		
Anglosarcoma	9120/3		
Rhabdomyosarcoma	8900/3		
Osteosarcoma	9180/3		
Leiomyoma	8890/0		
Lelomyosarcoma	8890/3		
FIREARD TURN IN THINANDS			
FIBROEPITHELIAL TUMOURS			
Fibroadenoma	9010/0		
Phyliodes turnour	9020/1		
Benign	9020/0		
Borderline	9020/1		
Malignant Periductal stromal turnour, low grade	9020/3		
Harnartoma	Bucuja		
The The Total Control			
TUMOURS OF THE NIPPLE			
Nipple adenoma	8506/0		
Syringomatous tumour	8407/0		
Paget disease of the nipple	8540/3		

<sup>\*</sup>The morphology codes are from the infernational Classification of Diseases for Oncology (ICD-0) [4838]. Behaviour is coded (0 for benign tumours, /1 for unspecified, borderine or uncertain behaviour, /2 for cardinoma in situ and grade III intraopithelial neoplasia, and /3 for malignant tumours; \*The classification is modified from the previous WHO histological classification of tumours (1413) taking into account changes in our understanding of these lesions. In the case of neuroendocrine neoplasms, the classification has been simplified to be of more practical utility in morphological classification; \*These new codes were approved by the IARIC/WHO Committee for ICD-0.

# 4. Specimen Requirement/Protocols for Histopathology Specimen

### A. Appropriate Handling of Large Breast Specimens

- > Time of removal from patient recorded on specimen requisition.
- Time from tissue acquisition to fixation should be as short as possible (preferably < 1 hour).</p>
- Specimen + requisition form transported fresh to the pathology dept.
- Opened, orientated, inked and sliced at 5mm intervals
- Placed in adequate volume of neutral buffered 10% formalin for a minimum of 6 hours to 72 hour.
- > Time placed in formalin recorded on the requisition form




WHY ALL THESE PROTOCOLS??????

### Fixation

Good fixative is most important in the production of satisfactory results in histopathology



Small intestine well preserved



Autolyzed Small intestine

# 4. Specimen Requirement/Protocols for Histopathology Specimen

### **B. Specimen Orientation**

- · Right breast lumpectomy
- Received fresh
- Suture
- identification (long lateral and short superior)

### C. Specimen Painting

- Margins identified and painted:
- Anterior yellow
- · Superior blue
- Posterior black
- Inferior red







# 4. Specimen Requirement/Protocols for Histopathology Specimen


### C. Specimen Slicing:

Specimen serially sectioned Lesion identified Margin proximity evident

#### D. Formalin Fixation:

Specimen prepared for form









## 4. Specimen Required for Histopathology



- Core-Needle Biopsy
- 2. Incisional Biopsy
- Excisional Biopsy or Lumpectomy:
  - Image-guided localization excisions
  - Without image-guided localization
  - Wide Local Excision
- 4. Total Mastectomy





# 4. Specimen Required for Histopathology


### 1. Core-Needle Biopsy: (Gold Standard)

- palpation guided used to sample a clinically palpable mass
- stereotactic used to sample mammographic findings (typically calcifications)
- ultrasound guided commonly used to sample mass lesions or MR findings with ultrasound correlates
- MRI guided used to sample findings not well visualized by other imaging modalities





### INCISIONAL BIOPSY



✓ Narrow, deep x Broad, shallow




### 4. Specimen Required.....cont

### 3. Excisional Biopsy or Lumpectomy:

Usually performed for complete removal of a targeted imaging or clinical finding for a known DCIS, invasive carcinoma, fibroepithelial lesion or other malignancy. Negative margins are a goal.

- Image-guided localization excisions: For non-palpable masses.
- Without image-guided localization: For palpable masses.
- Wide Local Excision





### 4. Specimen Requirement.....com

### 4. Total Mastectomy:

- Simple mastectomy: without removal of axillary lymph nodes.
- Skin sparing mastectomy: With removal of the nipple and only a narrow surrounding rim of skin.
- Nipple sparing mastectomy: without removal of skin or nipple.
- Modified radical mastectomy: total mastectomy with an axillary dissection.
- Radical mastectomy: total mastectomy with removal of the pectoralis major and pectoralis minor muscles as well as axillary contents.
- Toilet mastectomy: removal of breast in cases of locally advanced breast cancer for cosmetic reasons rather than being for curative purposes.





# 5. How Grading of the breast (2) cancer is done?

Feature	Score
Tubule formation (%)	
Majority of tumor (>75)	1
Moderate degree (10-75)	2
Little or none (<10)	3
Nuclear pleomorphism	
Small, uniform cells	1
Moderate increase in size/variation	2
Marked variation	3
Mitotic counts (per 10-40×fields)	
0-5 (histo) or 0-1 (cyto)	1
6-10 (histo) or 2-4 (cyto)	2
>11 (histo) or >5 (cyto)	3
Grade 1 (well-differentiated) (sum)	3-5
Grade 2 (moderately differentiated) (sum)	6-7
Grade 3 (poorly differentiated) (sum)	8-9
SRD-Scorff Bloom Dichardson	







Uniform cells with small nuclei similar in size to normal breast epithelial cells

#### **Mitotic Count:**

< 7 mitoses per 10 high power fields




Grade 2

#### **Nuclear Pleomorphism:**

Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in size and shape

#### **Mitotic Count:**

8-15 mitoses per 10 high power fields



Grade 3

#### Nuclear Pleomorphism:

Cells with vesicular nuclei, prominent nucleoli, marked variation in size and shape

#### **Mitotic Count:**

> 16 mitoses per 10 high power fields

### 6. Most common Breast Cancer Types

- Invasive ductal carcinoma of no special type (NST)
- Special subtypes:
- Invasive lobular carcinoma
- Tubular carcinoma
- · Carcinoma with medullary features
- Metaplastic carcinoma
- Carcinomas with apocrine differentiation
- Salivary gland/skin adnexal type tumors


Adenoid cystic carcinoma

Mucoepidermoid carcinoma

Polymorphous carcinoma

- · Mucinous carcinoma and carcinomas with signet-ring-cell differentiation
- · Carcinomas with neuroendocrine features
- · Invasive papillary carcinoma
- · Invasive micropapillary carcinoma
- · Inflammatory carcinoma





### TAKE HOME MESSAGE

- ALWAYS consider patient life as important as yours!
- 2. NEVER EVER waste any tissue or organ?
- 3. ALWAYS send the tissue or organ for histopathology
- 4. ALWAYS send the tissue or organ in 10% formalin
- 5. NEVER EVER divide the tissue to send to two pathologists
- 6. ALWAYS send intact and oriented tissue for HP
- 7. ALWAYS send with complete and proper history





